IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November.
| Event: | Protein & Antibody Engineering Summit (PEGS) Europe |
| Presenter: | Lawrence Lamb, Ph.D., Executive Vice President, Chief Scientific Officer and co-founder of IN8bio |
| Presentation: | A Pivotal Role for Concurrent Chemotherapy and γδ T Cell Therapy (Drug Resistant Therapy – DRI) in the Post-Induction Primary Disease Setting for Reducing the Immunosuppressive Properties of the Tumor Microenvironment |
| Date: | November 4 |
| Time: | 9 a.m. CET |
| Location: | Hotel Arts Ritz Carleton, Barcelona |
| Event: | Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting |
| Presenter: | Kate Rochlin, Ph.D., Vice President, Operations and Innovation at IN8bio |
| Presentation: | Poster 158: Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killing |
| Date: | November 13th |
| Time: | 7 to 8:30 p.m. EST |
| Location: | Walter E. Washington Convention Center, Washington, D.C. |
| Event: | Society for Neuro-Oncology 26th Annual Meeting |
| Presenter | Lei Ding, Ph.D., Staff Scientist – CAR T Lead, IN8bio |
| Presentation: | Poster: Dual chlorotoxin CAR and MGMT γδ T cells for drug resistant immunotherapy of glioblastoma multiforme |
| Date: | November 19 |
| Time: | 7:30 to 9:30 p.m. EST |
| Location: | Hynes Convention Center, Boston |
| Event: | Society for Neuro-Oncology 26th Annual Meeting |
| Sponsor: | IN8bio-sponsored academic research |
| Presenter: | Anita Hjelmeland, Ph.D., and Amber Jones |
| Presentation: | Poster: Enhancing Glioblastoma Cell Stress Response to Improve Gamma Delta T-Cell Immunotherapy |
| Date: | November 19 |
| Time: | 7:30 to 9:30 p.m. EST |
| Location: | Hynes Convention Center, Boston |
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
For more information about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6GDT (6438)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Solebury Trout
David Buck
+ 1 646.378.2927
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
+1 212.213.0006 - ext. 364 / 316
This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.78 |
| Daily Change: | -0.17 -8.72 |
| Daily Volume: | 57,011 |
| Market Cap: | US$8.240M |
November 06, 2025 October 29, 2025 October 27, 2025 June 09, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
